Venus Medtech (Hangzhou) Gestion

Gestion contrôle des critères 1/4

Le PDG Venus Medtech (Hangzhou) est Lin Haosheng Lim, nommé en Dec2016, a un mandat de 7.17 ans. La rémunération annuelle totale est CN¥ 1.26M, composée du salaire de 85.4% et des bonus 14.6%, y compris les actions et options de la société. détient directement 0.72% des actions de la société, d'une valeur de HK$ 17.67M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.9 ans et 2.9 ans.

Informations clés

Lin Haosheng Lim

Directeur général

CN¥1.3m

Rémunération totale

Pourcentage du salaire du PDG	85.4%
Durée du mandat du directeur général	7.2yrs
Propriété du PDG	0.7%
Durée moyenne d'occupation des postes de direction	1.9yrs
Durée moyenne du mandat des membres du conseil d'administration	2.9yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Lin Haosheng Lim a-t-elle évolué par rapport aux bénéfices de Venus Medtech (Hangzhou)?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2023	n/a	n/a	-CN¥1b
Mar 31 2023	n/a	n/a	-CN¥1b
Dec 31 2022	CN¥1m	CN¥1m	-CN¥1b
Sep 30 2022	n/a	n/a	-CN¥759m
Jun 30 2022	n/a	n/a	-CN¥461m
Mar 31 2022	n/a	n/a	-CN¥417m
Dec 31 2021	CN¥1m	CN¥694k	-CN¥374m

Rémunération vs marché: La rémunération totale de Lin Haosheng ($USD 175.50K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 375.53K ).

Rémunération et revenus: La rémunération de Lin Haosheng a augmenté alors que l'entreprise n'est pas rentable.

PDG

Lin Haosheng Lim (49 yo)

7.2yrs

Titularisation

CN¥1,263,000

Compensation

Mr. Hou-Sen Lim, also known as Lin Haosheng, MEng. Co-founded Transcatheter Technologies GmbH in 2009 and serves as its Managing Director and Chief Technology Officer. He serves as Chief Operating Officer...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Hou-Sen Lim	GM, COO & CTO	7.2yrs	CN¥1.26m	0.72% HK$ 17.7m
Fei Wang	Chief Financial Officer	less than a year	pas de données	pas de données
Joyce Heo	Director of Sales	1.9yrs	pas de données	pas de données
Christopher Richardson	Head of U.S. Operations	4.6yrs	pas de données	pas de données
Amir Gross	Head of Venus Global Heart Valve Innovation Center	1.9yrs	pas de données	pas de données
Shakeel Osman	Senior Vice President of Sales Europe	1.9yrs	pas de données	pas de données
Liu Meirong	Executive Director	1.1yrs	pas de données	pas de données
Liqiao Ma	Executive Director	less than a year	pas de données	0.0084% HK$ 208.0k
Wai Chiu Wong	Company Secretary	3.1yrs	pas de données	pas de données

1.9yrs

Durée moyenne de l'emploi

49yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 2500 n'est pas considérée comme expérimentée (ancienneté moyenne 1.9 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Liu Meirong	Executive Director	1.1yrs	pas de données	pas de données
Liqiao Ma	Executive Director	less than a year	pas de données	0.0084% HK$ 208.0k
Martin B. Leon	Member of Advisory Board	no data	pas de données	pas de données
Chaim Lotan	Member of Global Advisory Board	4.1yrs	pas de données	pas de données
Ting Yuk Wu	Independent Non-Executive Director	5.3yrs	CN¥423.00k	pas de données
Chi Wai Suen	Independent Non-Executive Director	4.6yrs	CN¥335.00k	pas de données
Wei Wang	Shareholders Representative Supervisor	5.3yrs	pas de données	pas de données
Scott Lim	Member of Global Advisory Board	4.1yrs	pas de données	pas de données
Min Shao	Employee Representative Supervisor	1.5yrs	pas de données	pas de données
Zhang Ao	Non-Executive Director	1.1yrs	pas de données	pas de données
Yue Li	Shareholders Representative Supervisor	1.8yrs	pas de données	pas de données

2.9yrs

Durée moyenne de l'emploi

48yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la 2500 n'est pas considéré comme expérimenté ( 2.9 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

Venus Medtech (Hangzhou) Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

Venus Medtech (Hangzhou) Inc. Announces Executive Changes

Recent updates

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

New minor risk - Share price stability

Venus Medtech (Hangzhou) Inc. Announces Executive Changes

No longer forecast to breakeven

Venus Medtech (Hangzhou) Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023

No longer forecast to breakeven

New minor risk - Profitability

Venus Medtech (Hangzhou) Inc. to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Share price stability

Founder recently bought HK$1.9m worth of stock

Venus Medtech (Hangzhou) Inc., Annual General Meeting, Jun 30, 2023

Venus Medtech (Hangzhou) Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary

Forecast to breakeven in 2025

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Board Changes

Insider recently sold HK$5.7m worth of stock

Venus Medtech (Hangzhou) Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman

Less than half of directors are independent

First half 2022 earnings released: CN¥0.46 loss per share (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

Venus Medtech (Hangzhou) Inc. to Report First Half, 2022 Results on Aug 31, 2022

China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System

Venus Medtech (Hangzhou) Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application

No longer forecast to breakeven

Forecast breakeven date pushed back to 2023

Venus Medtech (Hangzhou) Inc., Annual General Meeting, May 30, 2022

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2021 Results on Mar 31, 2022

Venus Medtech (Hangzhou) Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation Center

Venus Medtech (Hangzhou) Inc. Announces Completion of Global First Clinical Application of Venus-Powerx

Venus Medtech (Hangzhou) Inc. Announces Venus Vitae, Balloon-Expandable Dry Tissue Tavr System Successfully Completed the First Two Implantations in the Fim Clinical Trial

Venus Medtech (Hangzhou) Inc. (SEHK:2500) commences an Equity Buyback Plan for 43,170,744 shares, representing 9.79% of its issued share capital, under the authorization approved on May 21, 2021.

Forecast to breakeven in 2022

Forecast to breakeven in 2022

First half 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.11 loss in 1H 2020)

Forecast to breakeven in 2022

GM & Executive Director recently bought HK$35m worth of stock

GM & Executive Director recently bought HK$6.0m worth of stock

GM & Executive Director recently bought HK$30m worth of stock

Full year 2020 earnings released: CN¥0.45 loss per share (vs CN¥1.22 loss in FY 2019)

Full year 2020 earnings released: CN¥0.45 loss per share (vs CN¥1.22 loss in FY 2019)

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2020 Results on Mar 31, 2021

Venus Medtech (Hangzhou) Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.444843 billion.

GM & Executive Director recently sold HK$304m worth of stock

Venus Medtech (Hangzhou) Inc. Announces its CEP Device, TriGUARD3, Completes its First Clinical Application in the PRC

Venus Medtech (Hangzhou) Inc. Announces Change of Joint Company Secretary

COO, CTO & Executive Director recently sold HK$280m worth of stock

COO, CTO & Executive Director recently sold HK$193m worth of stock

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen